These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 28751953)
1. PCSK9 and carbohydrate metabolism: A double-edged sword. Filippatos TD; Filippas-Ntekouan S; Pappa E; Panagiotopoulou T; Tsimihodimos V; Elisaf MS World J Diabetes; 2017 Jul; 8(7):311-316. PubMed ID: 28751953 [TBL] [Abstract][Full Text] [Related]
2. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
4. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects. Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448 [TBL] [Abstract][Full Text] [Related]
5. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis. Lu X Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742 [TBL] [Abstract][Full Text] [Related]
6. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748 [TBL] [Abstract][Full Text] [Related]
7. Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture. Mbikay M; Sirois F; Simoes S; Mayne J; Chrétien M FEBS Open Bio; 2014; 4():755-62. PubMed ID: 25349780 [TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. Ferri N; Corsini A; Macchi C; Magni P; Ruscica M Transl Res; 2016 Jul; 173():19-29. PubMed ID: 26548330 [TBL] [Abstract][Full Text] [Related]
9. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study. Simonen P; Stenman UH; Gylling H Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271 [TBL] [Abstract][Full Text] [Related]
10. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways. Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia. Wu C; Xi C; Tong J; Zhao J; Jiang H; Wang J; Wang Y; Liu H Acta Pharm Sin B; 2019 Nov; 9(6):1216-1230. PubMed ID: 31867167 [TBL] [Abstract][Full Text] [Related]